Phenylethylamine in the CNS: effects of monoamine oxidase inhibiting drugs, deuterium substitution and lesions and its role in the neuromodulation of catecholaminergic neurotransmission
- PMID: 2193105
- DOI: 10.1007/978-3-7091-9050-0_12
Phenylethylamine in the CNS: effects of monoamine oxidase inhibiting drugs, deuterium substitution and lesions and its role in the neuromodulation of catecholaminergic neurotransmission
Abstract
Phenylethylamine is present in brain in tiny quantities, it is heterogeneously distributed and present in synaptosomes, and it is synthesized and degraded very quickly. If deuterium is substituted for hydrogen on the alpha carbon of the side chain then it exhibits profound isotope effects to MAO and its penetration and persistence in the brain is considerably enhanced. In the presence of MAO-B inhibitors treatment with reserpine causes reciprocal changes to PE and DA suggesting a functional relationship between them and after unilateral lesions of the substantia nigra an ipsilateral reduction in striatal PE is seen suggesting again a co-relationship with DA. Following iontophoresis PE has been shown to exhibit indirect sympathomimetic effects but in addition when applied at low currents concurrently with DA or NA it causes post synaptically a substantial potentiation in the actions of the latter amines. As a result of this and other data PE has been proposed to be a neuromodulator of catecholaminergic transmission.
Similar articles
-
Phenylethylaminergic modulation of catecholaminergic neurotransmission.Prog Neuropsychopharmacol Biol Psychiatry. 1991;15(2):139-56. doi: 10.1016/0278-5846(91)90076-d. Prog Neuropsychopharmacol Biol Psychiatry. 1991. PMID: 1651528 Review.
-
The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions.Neurochem Res. 1994 Feb;19(2):153-9. doi: 10.1007/BF00966810. Neurochem Res. 1994. PMID: 8183424
-
Reciprocal changes in striatal dopamine and beta-phenylethylamine induced by reserpine in the presence of monoamine oxidase inhibitors.Naunyn Schmiedebergs Arch Pharmacol. 1988 Dec;338(6):644-8. doi: 10.1007/BF00165628. Naunyn Schmiedebergs Arch Pharmacol. 1988. PMID: 3149722
-
Effects of deuterium substitution on the chronotropic responses to some sympathomimetic amines in the isolated rat atria.Naunyn Schmiedebergs Arch Pharmacol. 1987 Oct;336(4):391-5. doi: 10.1007/BF00164871. Naunyn Schmiedebergs Arch Pharmacol. 1987. PMID: 3124004
-
Functional interactions of 2-phenylethylamine and of tryptamine with brain catecholamines: implications for psychotherapeutic drug action.Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(3-4):431-43. doi: 10.1016/0278-5846(89)90131-0. Prog Neuropsychopharmacol Biol Psychiatry. 1989. PMID: 2664894 Review.
Cited by
-
Monoamine oxidases in development.Cell Mol Life Sci. 2013 Feb;70(4):599-630. doi: 10.1007/s00018-012-1065-7. Epub 2012 Jul 11. Cell Mol Life Sci. 2013. PMID: 22782111 Free PMC article. Review.
-
Plasma Biomarkers for Monitoring Brain Pathophysiology in FMR1 Premutation Carriers.Front Mol Neurosci. 2016 Aug 12;9:71. doi: 10.3389/fnmol.2016.00071. eCollection 2016. Front Mol Neurosci. 2016. PMID: 27570505 Free PMC article.
-
Trace amine-associated receptor 1-Family archetype or iconoclast?Pharmacol Ther. 2007 Dec;116(3):355-90. doi: 10.1016/j.pharmthera.2007.06.007. Epub 2007 Jul 17. Pharmacol Ther. 2007. PMID: 17888514 Free PMC article. Review.
-
Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.Rambam Maimonides Med J. 2010 Jul 2;1(1):e0003. doi: 10.5041/RMMJ.10003. Print 2010 Jul. Rambam Maimonides Med J. 2010. PMID: 23908775 Free PMC article.
-
Decreased beta-phenylethylamine in CSF in Parkinson's disease.J Neurol Neurosurg Psychiatry. 1997 Dec;63(6):754-8. doi: 10.1136/jnnp.63.6.754. J Neurol Neurosurg Psychiatry. 1997. PMID: 9416810 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials